Nearly one-third of adults with ANCA-associated vasculitis (AAV) would choose plasma exchange regardless of varying risks of kidney failure and severe infection, according to an international study. One-fifth of patients would make that choice only in high-risk scenarios and one-sixth would reject that treatment in all scenarios, however.
The blood levels of several immune-related proteins are significantly altered in people with ANCA-associated vasculitis (AAV) up to five years before they develop symptoms when compared with matched healthy people, a study showed. Changes in these protein levels were found to be involved in inflammatory and metabolic pathways, and…
Rituximab is superior to cyclophosphamide at inducing disease remission after six months in people with granulomatosis with polyangiitis (GPA) — a type of ANCA-associated vasculitis (AAV) — according to a study in France. Similar findings were found for subgroups of GPA patients, such as those newly diagnosed with the disease…
Blood levels of the soluble forms of CD28 and TIM-3 — two receptor proteins involved in the regulation of immune responses — are significantly associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) activity, a study showed. The levels of these so-called immune checkpoint molecules were increased in people with active AAV…
A 13-year-old girl developed ANCA-associated vasculitis (AAV) with major involvement of the central nervous system after COVID-19, a case study reports. “To our knowledge, this is the first reported pediatric case of ANCA-associated vasculitis with predominant central nervous system involvement after COVID-19 infection,” the researchers wrote. The girl had…
A 25-year-old man was diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA) after going to an outpatient clinic with joint pain and numbness in the hands and legs, according to a case study. He received treatment with corticosteroids and immunosuppressants, which stopped the EGPA progression and eased peripheral…
Get regular updates to your inbox.